Cargando…

Recent Development of Nuclear Molecular Imaging in Thyroid Cancer

Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes, cellular processes, and tumor microenvironment, molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huiting, Wang, Xiaoqin, Yang, Ran, Zeng, Wenbing, Peng, Dong, Li, Jason, Wang, Hu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987314/
https://www.ncbi.nlm.nih.gov/pubmed/29951528
http://dx.doi.org/10.1155/2018/2149532
_version_ 1783329086967382016
author Liu, Huiting
Wang, Xiaoqin
Yang, Ran
Zeng, Wenbing
Peng, Dong
Li, Jason
Wang, Hu
author_facet Liu, Huiting
Wang, Xiaoqin
Yang, Ran
Zeng, Wenbing
Peng, Dong
Li, Jason
Wang, Hu
author_sort Liu, Huiting
collection PubMed
description Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes, cellular processes, and tumor microenvironment, molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the most common endocrine malignancy, and its theranostic radioiodine has been widely used to diagnose or treat differentiated thyroid cancer. This article summarizes recent development of molecular imaging in thyroid cancer, which may accelerate the development of personalized thyroid cancer therapy.
format Online
Article
Text
id pubmed-5987314
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59873142018-06-27 Recent Development of Nuclear Molecular Imaging in Thyroid Cancer Liu, Huiting Wang, Xiaoqin Yang, Ran Zeng, Wenbing Peng, Dong Li, Jason Wang, Hu Biomed Res Int Review Article Therapies targeting specific tumor pathways are easy to enter the clinic. To monitor molecular changes, cellular processes, and tumor microenvironment, molecular imaging is becoming the key technology for personalized medicine because of its high efficacy and low side effects. Thyroid cancer is the most common endocrine malignancy, and its theranostic radioiodine has been widely used to diagnose or treat differentiated thyroid cancer. This article summarizes recent development of molecular imaging in thyroid cancer, which may accelerate the development of personalized thyroid cancer therapy. Hindawi 2018-05-21 /pmc/articles/PMC5987314/ /pubmed/29951528 http://dx.doi.org/10.1155/2018/2149532 Text en Copyright © 2018 Huiting Liu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Liu, Huiting
Wang, Xiaoqin
Yang, Ran
Zeng, Wenbing
Peng, Dong
Li, Jason
Wang, Hu
Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
title Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
title_full Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
title_fullStr Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
title_full_unstemmed Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
title_short Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
title_sort recent development of nuclear molecular imaging in thyroid cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987314/
https://www.ncbi.nlm.nih.gov/pubmed/29951528
http://dx.doi.org/10.1155/2018/2149532
work_keys_str_mv AT liuhuiting recentdevelopmentofnuclearmolecularimaginginthyroidcancer
AT wangxiaoqin recentdevelopmentofnuclearmolecularimaginginthyroidcancer
AT yangran recentdevelopmentofnuclearmolecularimaginginthyroidcancer
AT zengwenbing recentdevelopmentofnuclearmolecularimaginginthyroidcancer
AT pengdong recentdevelopmentofnuclearmolecularimaginginthyroidcancer
AT lijason recentdevelopmentofnuclearmolecularimaginginthyroidcancer
AT wanghu recentdevelopmentofnuclearmolecularimaginginthyroidcancer